ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2566

Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE

Dale Seguin1, Christine Peschken 2, Casandra Dolovich 1, Ruby Grymonpre 1, Phil St. John 1 and Annaliese Tisseverasinghe 1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: benzodiazepines and adults, opioids, polypharmacy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds),  is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially in older adults. Previously, we presented novel data on the prevalence and risk factors for polypharmacy and potentially inappropriate medications (PIMs), such as benzodiazepines and other sedative-hypnotics (BZD/Z-drugs), in older adults with SLE.  In this study we evaluate and compare polypharmacy and PIM use in all adults with SLE. Specific aims: 1.  Compare prevalence of polypharmacy [a) ≥5 and b) ≥10 meds] and PIM use [a) opioids, b) BZD/Z-drugs] between age groups (< 40 vs. ≥65, < 40 vs. ≥40, and < 65 vs. ≥65 years).   2.  Assess any association between polypharmacy, PIM use, and their potential risk factors, including age, sex, SLE duration, and rural residence.

Methods: Population:  Adults aged ≥18 years meeting ACR/SLICC SLE criteria and seen in our rheumatology clinic < 2 years ago.  For age < 50 years, every 3rd patient included. Patients lacking data in the Manitoba Drug Program Information Network (DPIN) were excluded.  Procedures:  All demographic and clinical variables were determined using data from electronic medical records. For unadjusted bi-variate analyses, we chose alpha of 5%.  Multivariable logistic regression models were constructed with inclusion of explanatory variables based on a priori clinical reasoning rather than stepwise selection.

Results: 271 patients included: 92% female, 13% < 3y SLE duration, 40% rural, 68% on ≥5 and 31% on ≥10 meds, 28% on BZD/Z-drugs, and 24% on opioids (Table 1). Prevalence of polypharmacy (≥5 meds) rose with age group (< 40 vs. 40-64 vs. ≥65 years), and was higher in women, rural residents, and SLE duration ≥3 years. Observations on ≥10 meds were similar except that sex difference was reversed (with fewer men).  Prevalence of BZD/Z-drugs increased with age, whereas opioid use peaked in 40-64 year-olds.  Prevalence of BZD/Z-drugs was higher in women, but opioid use higher in men.  Rural residents had higher prevalence of PIMs compared to urban dwellers.  The proportion of patients on BZD/Z-drugs was increased with SLE duration ≥3 years.  However, the null hypotheses that these inter-group differences are due to chance were not rejected based on our alpha (i.e. p > 0.05). In multivariable models, polypharmacy was associated with older age (OR 2.27, 95% CI 1.16-6.31 for  ≥40 vs. < 40 years for ≥5 meds ).  Opioids and BZD/Z-drugs were associated with polypharmacy (any definition) [OR 7.90 (95% CI 3.02-20.67) and 6.05 (2.63-13.96), respectively, for ≥5 meds].

Conclusion: This is the first study to investigate the prevalence and potential risk factors of polypharmacy and PIMs in SLE patients, including young adults.  According to this study, polypharmacy and PIM use are highly prevalent in SLE, and the prevalence of polypharmacy and BZD/Z-drugs appears to increase with age.  Moreover, PIM use is strongly associated with polypharmacy, independent of other patient characteristics. 

Our future goals are to include all eligible clinic patients in these analyses and to evaluate impact of polypharmacy and PIM use on SLE clinical outcomes.


Table 1

Table 1: Descriptive Statistics


Disclosure: D. Seguin, None; C. Peschken, Astra Zeneca, 2, Celgene, 2, Janssen, 2; C. Dolovich, None; R. Grymonpre, None; P. St. John, None; A. Tisseverasinghe, None.

To cite this abstract in AMA style:

Seguin D, Peschken C, Dolovich C, Grymonpre R, St. John P, Tisseverasinghe A. Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/polypharmacy-and-potentially-inappropriate-medication-use-in-young-versus-older-adults-with-sle/. Accessed January 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/polypharmacy-and-potentially-inappropriate-medication-use-in-young-versus-older-adults-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.